New diabetes drug candidate begins human testing in brazil
NCT ID NCT07518121
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new medicine called efsubaglutide alfa (YN-011) in 48 healthy adults in Brazil. The goal is to check the drug's safety, how the body processes it, and its effects. Participants receive a single injection of either the drug or a placebo and are monitored for about 4 weeks. This research helps determine if the drug is safe enough for future studies in people with type 2 diabetes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETE TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
A2Z Clinical Centro Avançado de Pesquisa Clínica LTDA
Valinhos, São Paulo, 13271-130, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could meal kits and text messages help curb diabetes in Food-Insecure communities?
- Walking downhill may boost heart health and strength in type 2 diabetes
- Could a simple supplement soothe diabetic nerve damage?
- Can family coaching cut diabetes risk? pilot study targets high-risk communities
- Home workouts via smartphone could help tame type 2 diabetes
- Can a chat with a nurse help control blood pressure and blood sugar?